Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing “commercial reasons” following a slump in demand.

“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied,” an AstraZeneca spokesperson added in a statement.

“We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic.”

AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020.

Vaxzevria, developed alongside Oxford University, was at first offered at cost but Astra decided in late 2021 to sell it for profit.

But the world pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer and German peer BioNTech, after rare blood-clot problems with Astra’s jab increased public hesitancy about taking it.

Last week, AstraZeneca admitted that its Covishield vaccine could cause rare side effects, including blood clots and low platelet count.

Sales collapsed further as global Covid restrictions were fully lifted worldwide and the world emerged from the global health crisis.

The AstraZeneca spokesperson said the group had begun the process of taking it off the market in the Europe, Middle East and Africa region.

The company will work with other regulators globally to start market authorisation withdrawals for the Vaxzevria “where no future commercial demand for the vaccine is expected”.

The spokesperson said that, according to independent estimates, “over 6.5 million lives were saved in the first year of use alone” and more than three billion doses were supplied globally.

“We are incredibly proud of the role Vaxzevria played in ending the global pandemic,” the spokesperson said.

“Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic.”

Opinion

Editorial

Counterterrorism plan
Updated 23 Nov, 2024

Counterterrorism plan

Lacunae in our counterterrorism efforts need to be plugged quickly.
Bullish stock market
23 Nov, 2024

Bullish stock market

NORMALLY, stock markets rise gradually. In recent months, however, Pakistan’s stock market has soared to one ...
Political misstep
Updated 23 Nov, 2024

Political misstep

To drag a critical ally like Saudi Arabia into unfounded conspiracies is detrimental to Pakistan’s foreign policy.
Kurram atrocity
Updated 22 Nov, 2024

Kurram atrocity

It would be a monumental mistake for the state to continue ignoring the violence in Kurram.
Persistent grip
22 Nov, 2024

Persistent grip

An audit of polio funds at federal and provincial levels is sorely needed, with obstacles hindering eradication efforts targeted.
Green transport
22 Nov, 2024

Green transport

THE government has taken a commendable step by announcing a New Energy Vehicle policy aiming to ensure that by 2030,...